We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/11/2022 17:22 | Nice summary Timbo, lots to look forward to here in the weeks& months ahead, share price getting noticed and gaining traction, be nice to see a repeat of the 100's of % increases from 6 weeks ago, fully expect it when next positive update drops GLA | georgie pie | |
30/11/2022 16:09 | Thanks Timbo- | pugugly | |
30/11/2022 16:05 | Evgen still look very good value compared to the IPO. When they IPOed back in 2015 (with an oversubscribed placing at 37p) they had a market cap of around £27m. The market cap now (circa £19m), is considerably lower than at the time of the IPO,(circa £27m), yet they have acheived so much since 2015, for example: * Developed a commercialisable tablet form of SFX-01, no mean feat when you consider all they had in 2015 was hand filled capsules for proof of concept work * Signed a marketing deal for a stable form of the natural form of sulforaphane with Juvenescence (worth $10.5m plus royalties) * Completed a successful proof of concept study using synthetic sulforaphane (SFX-01) for metabolic breast cancer * Signed a deal with Stalicla for the use of synthetic sulforaphane (SFX-01) for neurological indications including Autism (worth up to $160m plus royalties) * Made considerable preclinical progress with third party collaborators for various oncology indications such as glioblastoma and leukaemia They have had two clinical "failures" both of which were extreme long shots (subarachnoid haemorrhagic stroke and Pneumonia associated with Covid and other respiratory viral infections) - but the silver lining to that is that a least they are not going to spend further shareholder funds investigating these two non-starters. Having said that, I still wouldn't right off SFX-01 for long covid at some stage in the future (funded by Stalicla?), espcially when you consider the very high prevalence of long covid (and ME) in patients with the Autism spectrum disorder (google search for Long COVID and autism to see the links) | timbo003 | |
30/11/2022 14:52 | hard to buy in quantity | georgie pie | |
30/11/2022 13:41 | Bound to be profit taking. But as can seen from the header the potential is well into double figures. | manual dexterity | |
30/11/2022 13:14 | Could be - but think it's more that people are starting to see the chasm in value | givmesunshine | |
30/11/2022 13:07 | This is some serious buying - must be more to this than meets the eye imo -8p today? | clocktower | |
30/11/2022 13:00 | That would be nice. | manual dexterity | |
30/11/2022 12:50 | 10p incoming | wololol | |
30/11/2022 12:49 | hmmm...I think something may be going on here .. | givmesunshine | |
30/11/2022 12:20 | Hi All - I think we all know this is worth multples of the current share price .. good to see it rerate though.. how many AIM BIOs can land a £160million licencing deal on a project that is a side line investment and still be valued so low | givmesunshine | |
30/11/2022 11:45 | Looking much better! | manual dexterity | |
30/11/2022 11:28 | I will agree with that mark! :-) Might wake up one day to an offer for EVG from F imo | clocktower | |
30/11/2022 11:22 | Wouldnt indeed but it would be very nice! | markth126 | |
30/11/2022 11:19 | I'll add to my post 888 - The drugs that EVG etc have and are developing might well be life changing to those that benefit from the research and results. | clocktower | |
30/11/2022 11:12 | LOL mark - Sorry I had to chuckle at your post 887 - I don't think it will change your or mind life even if it hits £1.00 . | clocktower | |
30/11/2022 10:57 | This could be a life changing share given the correct deals and results. Holding for the long term | markth126 | |
30/11/2022 10:46 | Lets see if we can get to 7p+. Longer term most of us have an inkling on where EVG could go. | manual dexterity | |
30/11/2022 09:33 | Was thinking the same CT, i feel a breakout coming. | georgie pie | |
30/11/2022 09:14 | Good morning all Another good start to the day - with luck we might move up to 6.5/7p today imo Day after day it looks more solid which is really pleasing. Slowly slowly towards 8p | clocktower | |
30/11/2022 08:56 | News must be close MD, sentiment is very strong here now and i expect it to keep ticking up the rest of the week, just my view. | georgie pie | |
30/11/2022 08:43 | Indeed. 6p+ EVG is in a good space and we just need updates now. | manual dexterity | |
30/11/2022 08:22 | 6p just paid, highest price for about 6 weeks, the trend is with us. | georgie pie | |
30/11/2022 08:17 | Fully expecting 6 to go today, agree with Clocktower more here on current sentiment alone and with next news closer by the day maybe another massive rally if RNS is mega positive. | georgie pie | |
29/11/2022 15:47 | I think there is another 30% in this even without news, as the raise was done at 8p Then to rocket it we need another deal or two. | clocktower |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions